Bernardo Flasterstein
Neurology with Special Qualifications in Child Neurology · Loxahatchee, FLNPI 1649325051
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Ironshore Pharmaceuticals Inc. accounts for 67.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $10,393 and has fallen 94.1% since, to $618 in 2025.
Across 87 payments — averaging $147.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$9K
- Livanova USA, Inc.$1K
- UCB, Inc.$1K
- Supernus Pharmaceuticals, Inc.$202
- Neurelis, Inc.$186
- Greenwich Biosciences, Inc.$163
- plus $860 from 14 others
Across 98 payments — averaging $3533.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$174K
- Eisai Inc.$97K
- H. Lundbeck A S$29K
- AbbVie$16K
- UCB SA$11K
- Upsher-smith Laboratories LLC$10K
- plus $9K from 3 others
What the payments were for
- Speaking & faculty fees$5,67044%
- Travel & lodging$3,47427%
- Food & beverage$3,66429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 25 | $8,702 |
| Livanova USA, Inc. | 7 | $1,430 |
| UCB, Inc. | 22 | $1,265 |
| Supernus Pharmaceuticals, Inc. | 4 | $202 |
| Neurelis, Inc. | 6 | $186 |
| Greenwich Biosciences, Inc. | 2 | $163 |
| Acadia Pharmaceuticals Inc | 2 | $149 |
| Genentech USA, Inc. | 3 | $133 |
| SK Life Science, Inc. | 2 | $127 |
| Eisai Inc. | 1 | $122 |
| Jazz Pharmaceuticals Inc. | 3 | $79 |
| Harmony Biosciences LLC | 1 | $50 |
| Biomarin Pharmaceutical Inc. | 2 | $35 |
| Biocodex, Inc. | 1 | $26 |
| Aquestive Therapeutics, Inc. | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Corium, LLC | 1 | $24 |
| Tris Pharma Inc | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$8,231
- VNS Therapy$1,408
- Fintepla$592
- Epidiolex$139
- DAYBUE$125
- Fycompa$122
- QELBREE$121
How this compares
$12,808 in reported general payments places this provider in the 70th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Loxahatchee
- Edwin LiuLoxahatchee$5K
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.